MGY825 is a KRAS inhibitor in a Phase 1 clinical trial for non-small cell lung cancer (NSCLC) patients with NRF2, KEAP1, or CUL3 mutations (NCT05275868). Here, NFE2L2 is linked to non-small cell lung carcinoma.